The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) is a huge mover today! About 125,524 shares traded hands or 64.16% up from the average. Dimension Therapeutics Inc (NASDAQ:DMTX) has declined 28.21% since April 13, 2016 and is downtrending. It has underperformed by 32.14% the S&P500.
The move comes after 7 months negative chart setup for the $131.58M company. It was reported on Nov, 15 by Barchart.com. We have $4.77 PT which if reached, will make NASDAQ:DMTX worth $13.16M less.
Analysts await Dimension Therapeutics Inc (NASDAQ:DMTX) to report earnings on December, 2. They expect $-0.50 EPS, up 81.68% or $2.23 from last year’s $-2.73 per share. After $-0.49 actual EPS reported by Dimension Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.04% negative EPS growth.
Dimension Therapeutics Inc (NASDAQ:DMTX) Ratings Coverage
Out of 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dimension Therapeutics has been the topic of 9 analyst reports since November 6, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald initiated Dimension Therapeutics Inc (NASDAQ:DMTX) on Friday, June 3 with “Buy” rating. The company was initiated on Monday, November 16 by Citigroup. The company was initiated on Monday, November 16 by Canaccord Genuity. The rating was initiated by Roth Capital on Friday, November 6 with “Buy”. The company was initiated on Friday, December 4 by Wells Fargo. Goldman Sachs initiated the shares of DMTX in a report on Friday, December 4 with “Buy” rating. Goldman Sachs initiated the shares of DMTX in a report on Monday, November 16 with “Buy” rating. The rating was initiated by Cantor Fitzgerald with “Buy” on Thursday, February 18.
According to Zacks Investment Research, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.”
More news for Dimension Therapeutics Inc (NASDAQ:DMTX) were recently published by: Marketwatch.com, which released: “Dimension Therapeutics Inc.” on July 22, 2014. Wsj.com‘s article titled: “In Latest Setback for Biotech IPOs, Dimension Therapeutics Shares Fall in Debut” and published on October 22, 2015 is yet another important article.
DMTX Company Profile
Dimension Therapeutics, Inc., incorporated on June 20, 2013, is a gene therapy company. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The Firm has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV) vector delivery technology. The Firm uses mammalian cells in its manufacturing approach for its AAV product candidates. The Company’s AAV manufacturing is performed in over two mammalian cell types, human embryonic kidney 293 cells (HEK293 cells) and HeLa cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.